Company: CMND
Filing Date: 2025-01-22
Form Type: 20-F
Source: 0001213900-25-005490
Chunk: 188

Company: Clearmind Medicine Inc.
Filing Date: 2025-01-22
Form: 20-F
Item: Item 6
Chunk 188
---
───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

C. Board Practices

Except as stated below, we intend to comply with
the rules generally applicable to U. S. domestic companies listed on the Nasdaq. We may in the future decide to use other foreign private
issuer exemptions with respect to some of the other Nasdaq listing requirements. Following our home country governance practices, as opposed
to the requirements that would otherwise apply to a company listed on the Nasdaq, may provide less protection than is accorded to investors
under the Nasdaq Rules applicable to U. S. domestic issuers.

The Canadian securities regulatory authorities
have issued corporate governance guidelines pursuant to National Policy 58-201 - Corporate Governance Guidelines, or the Corporate
Governance Guidelines, or NP 58-201, together with certain related disclosure requirements pursuant to National Instrument 58-101 - Disclosure
of Corporate Governance Practices, or NI 58-101. The Corporate Governance Guidelines are recommended as “guidance” for
issuers to follow. We recognize that good corporate governance plays an important role in our overall success and in enhancing shareholder
value and, accordingly, we have adopted certain corporate governance policies and practices which reflect our consideration of the recommended
Corporate Governance Guidelines.

The disclosure set out below includes disclosure
required by NI 58-101 describing our approach to corporate governance in relation to the Corporate Governance Guidelines.

Composition of our Board

Under our articles of incorporation, our Board
is to consist of three directors and up to that number which was last set by ordinary resolution of the shareholders. We currently have
four directors and under the BCBCA, as a reporting issuer, we must have no fewer than three directors. Under the BCBCA, a director may
be removed with or without cause, prior to expiration of the director’s term, by a resolution passed by at least two-thirds of the
votes cast by shareholders present in person or by proxy at a meeting and who are entitled to vote. The directors are appointed at the
annual general meeting of shareholders and the term of office for each of the directors will expire at the time of our next annual shareholders
meeting. Our articles of incorporation provide that, between annual general meetings of our shareholders, the directors may appoint one
or more additional directors, but the number of additional directors may not at any time exceed one-third of the number of directors who
held office at the expiration of the last meeting of our shareholders. Under the BCBCA